METHODS OF TREATING CANCER
Methods for treating a human having heptocellular carcinoma comprising administering to the human a therapeutically effective amount of Compound A: or a pharmaceutically acceptable salt thereof, wherein the human has a complete response or partial response.
1 . A method of treating a human having heptocellular carcinoma comprising administering to said human a therapeutically effective amount of Compound A:
or a pharmaceutically acceptable salt thereof, wherein said human has a complete response or partial response.
2 . The method of claim 1 , wherein said human has complete response.
3 . The method of claim 1 , wherein said human has partial response.
4 . The method of claim 1 , wherein said complete or partial response is measured by a modified RECIST criteria.
5 . The method of claim 1 , wherein said complete or partial response is measured by RECIST 1.0 criteria.
6 . The method of claim 1 , wherein Compound A is administered as a free base.
7 . The method of claim 1 , wherein Compound A is administered at a dose of at least 7.5 mg daily.
8 . The method of claim 1 , wherein Compound A is administered at a dose of at least about 30 mg daily.
9 . The method of claim 1 , wherein said hepatocellular carcinoma is unresectable or metastatic.
10 . The method of claim 1 , wherein said human has not previously received another multiple receptor tyrosine kinase inhibitor.
11 . The method of claim 1 , wherein said Compound A is administered as monotherapy.
12 . A method of treating a human in need thereof comprising administering to said human 30 mg and/or 45 mg of Compound A, wherein said human has hepatocellular cancer.
13 . (canceled)
14 . (canceled)
15 . A method inducing a complete response in a human comprising administering to said human a therapeutically effective amount of Compound A:
or a pharmaceutically acceptable salt thereof, wherein said human has heptocellular carcinoma.